Effective GDNF brain delivery using microspheres—A promising strategy for Parkinson's disease

The rat brain in stereotaxic coordinates

Palkovits, M. (1983) · Neuropeptides · doi:10.1016/0143-4179(83)90049-5 · Cited by 28,959

The Rat Brain in Stereotaxic Coordinates

Paxinos, G., & Watson, C. (1983) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 28,585

GDNF: a Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic Neurons

Lin, L.-F. H., Doherty, D. H., Lile, J. D., Bektesh, S. L., & Collins, F. (1993) · Science · doi:10.1126/science.8493557 · Cited by 3,206

Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease

Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290

Neurodegeneration Prevented by Lentiviral Vector Delivery of GDNF in Primate Models of Parkinson's Disease

Kordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J. L., Chen, E., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251

Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease

Lang, A. E., Gill, S., Patel, N., Lozano, A., Nutt, J. G., Penn, R., Brooks, D. J., Hotton, G. R., Moro, E., Heywood, P., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20737 · Cited by 987

Characterization of Behavioral and Neurodegenerative Changes Following Partial Lesions of the Nigrostriatal Dopamine System Induced by Intrastriatal 6-Hydroxydopamine in the Rat

Kirik, D., Rosenblad, C., & Björklund, A. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6848 · Cited by 663

Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line—derived neurotrophic factor

Slevin, J. T., Gerhardt, G. A., Smith, C. D., Gash, D. M., Kryscio, R. J., & Young, B. A. (2005) · Journal of neurosurgery · doi:10.3171/jns.2005.102.2.0216 · Cited by 474

Intraputamenal infusion of glial cell line–derived neurotrophic factor in PD: A two‐year outcome study

Patel, N. K., Bunnage, M., Plaha, P., Svendsen, C. N., Heywood, P. G., & Gill, S. S. (2005) · Annals of Neurology · doi:10.1002/ana.20374 · Cited by 384

Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility

Fournier, E., Passirani, C., Montero‐Menei, C. N., & Benoît, J. (2003) · Biomaterials · doi:10.1016/s0142-9612(03)00161-3 · Cited by 353

Basic Principles of Peripheral Nerve Disorders

Rayegani, S. M. (2012) · InTech eBooks · doi:10.5772/1249 · Cited by 16

Materials for Central Nervous System Tissue Engineering

Pérez-Garnes, M., Barcia, J. A., Gómez‐Pinedo, U., Pradas, M. M., & Vallés‐Lluch, A. (2014) · InTech eBooks · doi:10.5772/59339 · Cited by 12

Stem Cells, Bioengineering, and 3-D Scaffolds for Nervous System Repair and Regeneration

Sandquist, E. J., Uz, M., Sharma, A. D., Patel, B. B., Mallapragada, S. K., & Sakaguchi, D. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-31433-4_2 · Cited by 12

Stem Cell Therapy for Neurodegenerative Diseases

Yee, J. Z., Oh, K., & Kim, S. H. (2015) · Hanyang Medical Reviews · doi:10.7599/hmr.2015.35.4.229 · Cited by 12

Preparation of bioactive glycosylated glial cell‐line derived neurotrophic factor‐loaded microspheres for medical applications

Niyomthai, S. T., Israsena, N., Boonkrai, C., & Supaphol, P. (2013) · Journal of Applied Polymer Science · doi:10.1002/app.40168 · Cited by 10

H2O2- or l-DOPA-injured dopaminergic neurons trigger the release of soluble mediators that up-regulate striatal GDNF through different signalling pathways

Fonseca, C. P., Gama, S., Saavedra, A., & Baltazar, G. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.03.003 · Cited by 9

Controlled delivery of bioactive BDNF for potential treatment of peripheral nerve injury

Zeng, W., Chang, Z., Liu, Z., Zhu, L., Wang, M., Hao, D., & He, B. (2020) · Polymer Degradation and Stability · doi:10.1016/j.polymdegradstab.2020.109296 · Cited by 9

Growth Factor Therapy for Parkinson’s Disease: Alternative Delivery Systems

Jarrin, S., Hakami, A., Newland, B., & Dowd, E. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212662 · Cited by 9

Enhanced growth and differentiation of neural stem cells on alginate/collagen/reduced graphene oxide composite hydrogel incorporated with lithium chloride

Babaei, A., Tiraihi, T., Ai, J., & Baheiraei, N. (2023) · Bioimpacts · doi:10.34172/bi.2023.24266 · Cited by 8

Morphological Changes in a Severe Model of Parkinson’s Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors

Requejo, C., Ruíz-Ortega, J. Á., Bengoetxea, H., García-Blanco, A., Herrán, E., Aristieta, A., Igartúa, M., Pedraz, J. L., Ugedo, L., Hernández, R. M., et al. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0244-1 · Cited by 8

Advances in Tissue Engineering and Regeneration

Ghosal, K., Sarkar, P., Saha, R., Ghosh, S., & Sarkar, K. (2020) · Springer eBooks · doi:10.1007/978-3-030-34471-9_22 · Cited by 8

Unraveling the Ties: Type 2 Diabetes and Parkinson's Disease - A Nano-Based Targeted Drug Delivery Approach

De, S., Banerjee, S., Rakshit, P., Banerjee, S., & Kumar, S. K. A. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998291968240429111357 · Cited by 6

Optimization of a GDNF production method based on Semliki Forest virus vector

Torres-Ortega, P. V., Smerdou, C., Ansorena, E., Ballesteros-Briones, M. C., Martišová, E., Garbayo, E., & Blanco‐Prieto, M. J. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105726 · Cited by 6

GDNF-loaded composite microspheres enhanced porous-oriented conduits for peripheral nerve regeneration

Yalikun, A., Wang, S., Li, L., Liu, K., Hamiti, Y., & Yusufu, A. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.165574 · Cited by 5

Antiparkinsonian Agents in Investigational Polymeric Micro- and Nano-Systems

Paccione, N., Rahmani, M., Barcia, E., & Negro, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010013 · Cited by 5

Nanocarriers to mediate the pathways from diabetes toward Parkinson's disease

De, S., & Kuo, Y. (2024) · Journal of the Taiwan Institute of Chemical Engineers · doi:10.1016/j.jtice.2024.105401 · Cited by 6

Revolutionizing fixed-dose combinations with long-acting microsphere

Hu, Z., Xiao, X., Zhang, G., & Li, Y. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107032 · Cited by 4

Brain targeting drug delivery systems for the management of brain disorders

Kaur, M., Sodhi, R. K., Jyothi, V. G. S. S., Sree, V. H., Shubhra, Singh, P. K., Mehra, N. K., Khatri, D. K., Srivastava, S., Singh, S. B., et al. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85041-4.00012-3 · Cited by 4

Nanotechnology Based Approaches for Neurodegenerative Disorders: Diagnosis and Treatment

Hernando, S., Herrán, E., Pedraz, J. L., Igartúa, M., & Hernández, R. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-57696-1_3 · Cited by 4

Nanobiotechnology in Parkinson’s Disease

Torres-Ortega, P. V., Martínez-Valbuena, I., Martí‐Andrés, G., Hanafy, A. S., Luquin, M. R., Garbayo, E., & Blanco‐Prieto, M. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-30930-5_7 · Cited by 4

Stem-cell therapy for neurologic diseases

Sharma, S., & Gupta, D. K. (2015) · Journal of Neuroanaesthesiology and Critical Care · doi:10.4103/2348-0548.148379 · Cited by 4

Multi-target monoamine oxidase-B (MAO-B) inhibitors in the treatment of Parkinson’s disease

Mateev, E., Pavlova, E., Kostov, S., Irfan, A., Mateeva, A., Kondeva-Burdina, M., & Momekov, G. (2025) · Pharmacia · doi:10.3897/pharmacia.72.e164727 · Cited by 3

Parkinson's Disease: Cell Vulnerability and Disease Progression

de Tassigny, X. D., Pascual, A., & López‐Barneo, J. (2015) · Frontiers research topics · doi:10.3389/978-2-88919-676-0 · Cited by 3

Parkinson's disease

Bhatt, T., Patel, B. M., & Patel, M. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819838-4.00028-6 · Cited by 3

6.19 Biomaterials for Central Nervous System Regeneration

Tysseling, V. M., & Kessler, J. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-08-100691-7.00036-7 · Cited by 3

Blood-to-Brain Drug Delivery Using Nanocarriers

Hu, Y., Gaillard, P. J., Rip, J., & Hammarlund‐Udenaes, M. (2022) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-88773-5_16 · Cited by 2

Controlled Release Strategy Based on Biodegradable Microspheres for Neurodegenerative Disease Therapy

Gu, H., & Yue, Z. (2012) · InTech eBooks · doi:10.5772/29769 · Cited by 2

Biomaterials for Central Nervous System Regeneration

Tysseling, V. M., & Kessler, J. A. (2011) · Elsevier eBooks · doi:10.1016/b978-0-08-055294-1.00185-9 · Cited by 2

Drug delivery systems for engineering neural tissue

Willerth, S. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-811385-1.00007-8 · Cited by 2

Drug Delivery in Tissue Engineering: General Concepts

Simón‐Yarza, T., Garbayo, E., Tamayo, E., Prósper, F., & Blanco‐Prieto, M. J. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849735292-00501 · Cited by 1

Neuroprotective compounds and innovative therapeutic strategies for Parkinson’s disease: experimental and clinical studies

Blandini, F. (2009) · Open Access Journal of Clinical Trials · doi:10.2147/oajct.s4660 · Cited by 1

Regenerative and Repair Strategies for the Central Nervous System

Sakaguchi, D. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-44022-4_47 · Cited by 2

A Microfluidic Platform to Investigate the Mechanism by which GDNF Overexpression in Schwann Cells Causes Neuronal Axon Entrapment

Wang, Z. Z. (2020) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k1zb-q206 · Cited by 1

Implantable and long-lasting drug delivery systems for infectious, inflammatory, endocrine, and neurodegenerative diseases

Mathew, E., Stewart, S. A., Utomo, E., Larrañeta, E., & Lamprou, D. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821749-8.00003-3 · Cited by 1

Enhancement of Peripheral Nerve Regeneration with Controlled Release of Glial Cell Line-derived Neurotrophic Factor (GDNF)

Tajdaran, K. (2015) · TSpace (University of Toronto) · Cited by 1

Expressão de GDNF em células estriatais: efeito de fatores solúveis libertados por células do mesencéfalo ventral após lesão dopaminérgica

Gama, S. (2012) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)

Controlled Delivery of Therapeutic Proteins to the Injured Spinal Cord

Donaghue, I. E. (2016) · TSpace (University of Toronto)

Tissue engineering for reconstructing the central dopaminergic nigro-striatal pathway in Parkinson’s disease: Cutting edge cell culture studies

Schurig, K. (2011) · Qucosa (Saxon State and University Library Dresden)

Infusion Therapy for Movement Disorders

Barua, N. U., & Gill, S. S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-805353-9.00080-2

Growth factor loaded-microparticles as a tool for cardiac repair

Rocha, F. G. (2014) · Deposito Adademico Digital Universidad De Navarra (University of Navarra)

Development of three-dimensional biomaterials containing stem cells and neurotrophic factors for brain repair in Parkinson's disease

Torres-Ortega, P. V. (2021) · doi:10.15581/10171/63294

Optimization of mimetic periosteum autografts for the treatment of nonunions

Romero-Torrecilla, J. A. (. A. (2023) · doi:10.15581/10171/68418

Design, Optimization and In Vitro Neuroprotective Assessment of Rasagiline Mesylate-loaded PLGA Microspheres for the Parkinson’s Disease Management

Chaudhari, N., Khude, H., & Pai, R. V. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-10578-y

Caractérisation de P42, région cruciale pour la fonction de la Huntingtine et peptide capable d’inhiber la toxicité associée à la Chorée de Huntington

Arribat, Y. (2012) · theses.fr (ABES) · doi:10.70675/5aa6e3f4zde48z42f6z8275z02764f961d3a

Polyphosphoesters for the design of organic and inorganic drug delivery systems.

Ergül, Z. (2015) · doi:10.70675/1374551bz40acz461fzaee9z2a80d4aea6c6

Récupérations sensorimotrices après lésion du système nerveux central et périphérique : utilisation de biomatériaux et de cellules souches

Bonnet, M. (2020) · theses.fr (ABES) · doi:10.70675/0b579c62z6b36z44a8za587zeefa7bc5add6

An injectable nanoreinforced hydrogel for combined GDNF-loaded nanoparticles and mesenchymal stem cell therapy in Parkinson’s disease

Campo-Montoya, R. D., Piera, X. M. I., García-Gómara, M., Alfaro, M., Chocarro, J., Ilarduya, M. M., Lanciego, J. L., Luquin, M. R., Cuadrado‐Tejedor, M., García‐Osta, A., et al. (2026) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2026.107597

Emerging nano-drug delivery strategies for management of neuropsychiatric disorders

Jaiswal, A. K., Zai, I., Hasan, N., & Sultana, Y. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108806

Convergent Astrocytic Failure in Parkinson’s Disease: A System-Level Model of Pathogenesis and Treatment

Abdelaziz, A. M., Fawzy, M. N., & Shokr, M. M. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06177-0

Formulations of Lazaroid-U74389G for Organ Targeting and Potential Chemotherapy

Ibrahim, F. (2011)

Xenogeneic delivery of therapeutic products using transient immunosuppression

Park, K. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.06.001

Is apoptosis involved in the nigral neuronal death in Parkinson's disease?

Sugita, Y., & Mizuno, Y. (1998) · Pathophysiology · doi:10.1016/s0928-4680(98)81201-7

Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease

Jollivet, C., Aubert‐Pouëssel, A., Clavreul, A., Venier‐Julienne, M., Remy, S., Montero‐Menei, C. N., Benoît, J., & Meneï, P. (2003) · Biomaterials · doi:10.1016/s0142-9612(03)00601-x · Cited by 103

Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease

Gouhier, C., Chalon, S., Aubert‐Pouëssel, A., Venier‐Julienne, M., Jollivet, C., Benoît, J., & Guilloteau, D. (2002) · Synapse · doi:10.1002/syn.10063 · Cited by 41

Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease

Jollivet, C., Aubert-Pouessel, A., Clavreul, A., Venier-Julienne, M.-C., Montero-Menei, C. N., Benoit, J.-P., & Menei, P. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2003.11.051 · Cited by 43